New use possible for Lilly's Evista

July 20, 2007
Eli Lilly and Co. may have found a new use for its osteoporosis drug Evista, according to Bloomberg.

The U.S. Food and Drug Administration said Evista reduced the risk of certain invasive breast cancers in post-menopausal women.

However, studies from Indianapolis-based Lilly provided weaker support for Evista's ability to help women at high risk of developing breast cancer, the FDA said.

Evista is a $1 billion a year drug, but Lilly wants to find new uses for it because analysts expect its sales to tail off gradually over the next several years. Lilly has a patent on Evista until 2014.
Source: XMLFULL/XMLFull3212.xml

Recent Articles by IBJ Staff

Comments powered by Disqus